ZYVERSA THERAPEUTICS, INC. Payments of Financing Costs
ZYVERSA THERAPEUTICS, INC. (ZVSA) reported Payments of Financing Costs of $282.85 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2026-05-13
- ZYVERSA THERAPEUTICS, INC. payments of financing costs for the quarter ending 2026-03-31 was $282.85K, a 0.00% change year-over-year.
- ZYVERSA THERAPEUTICS, INC. payments of financing costs for the quarter ending 2025-12-31 was -$167.75K.
- ZYVERSA THERAPEUTICS, INC. payments of financing costs for the quarter ending 2025-09-30 was $175.22K, a 58.97% decline year-over-year.
- ZYVERSA THERAPEUTICS, INC. payments of financing costs for the quarter ending 2025-06-30 was $0.00.
- ZYVERSA THERAPEUTICS, INC. payments of financing costs for fiscal 2025 was $290.32K, a 36.88% increase from fiscal 2024.
- ZYVERSA THERAPEUTICS, INC. payments of financing costs for fiscal 2024 was $212.10K, a 91.13% decline from fiscal 2023.
- ZYVERSA THERAPEUTICS, INC. payments of financing costs for fiscal 2023 was $2.39M.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2026-03-31 | $282.85K 10-Q · filed 2026-05-13 | $115.10K derived: sum of 2 quarters · filed 2026-05-13 | $290.32K derived: sum of 3 quarters · filed 2026-05-13 | $290.32K derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | -$167.75K derived: 10-K 12 month − 3 quarters · filed 2026-03-31 | $7.47K derived: sum of 2 quarters · filed 2026-03-31 | $7.47K derived: sum of 3 quarters · filed 2026-03-31 | $290.32K 10-K · filed 2026-03-31 |
| 2025-09-30 | $175.22K 10-Q · filed 2025-11-19 | $175.22K derived: sum of 2 quarters · filed 2025-11-19 | $458.07K derived: sum of 3 quarters · filed 2025-11-19 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $282.85K 10-Q · filed 2025-08-13 | ||
| 2025-03-31 | $282.85K 10-Q · filed 2025-11-19 | |||
| 2024-12-31 | $212.10K 10-K · filed 2026-03-31 | |||
| 2024-09-30 | $427.05K 10-Q · filed 2025-11-19 | |||
| 2023-12-31 | $2.39M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $523.12K 10-Q · filed 2024-11-14 | $1.71M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $1.18M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |